Merck
  • Home
  • Search Results
  • Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.

Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.

Clinical journal of the American Society of Nephrology : CJASN (2007-08-21)
Peter Stenvinkel, Ernesto Rodríguez-Ayala, Ziad A Massy, Abdul Rashid Qureshi, Peter Barany, Bengt Fellström, Olof Heimburger, Bengt Lindholm, Anders Alvestrand
ABSTRACT

Myeloperoxidase (MPO), which is secreted during activation of neutrophils, may serve as one mechanistic link among persistent inflammation, oxidative stress, and cardiovascular disease. This study related MPO activity to inflammatory and oxidative stress biomarkers, comorbidity, and ongoing medication in prevalent hemodialysis (HD) patients. In a cross-sectional evaluation of 115 prevalent (vintage 25 mo) HD patients (62 men; 63 +/- 1 yr), data on comorbidity (Davies score), diabetes, medication (statins and antihypertensive drugs), nutritional status (subjective global assessment), blood lipids (cholesterol, HDL cholesterol, and triglycerides), inflammatory biomarkers (serum albumin, C-reactive protein, TNF-alpha, and IL-6), oxidative stress biomarkers (pentosidine, 8-hydroxydeoxyguanosine, and MPO activity) were recorded. Patients with MPO activity greater than the median had significantly (P < 0.05) lower serum albumin levels (33.2 +/- 0.7 versus 35.0 +/- 0.5 g/L), higher 8-hydroxydeoxyguanosine levels (1.26 +/- 0.08 versus 1.05 +/- 0.06 ng/ml), and a lower prevalence of statin treatment (18 versus 36%). Therefore, the median MPO activity was significantly (P < 0.05) lower (17.7 versus 26.6 deltaOD630/min per mg protein) in the subgroup of 31 HD patients with ongoing statin treatment. In a multiple regression model, correction for the impact of age, gender, vintage, serum cholesterol, serum albumin, comorbidity, diabetes, and statin use, only diabetes (P < 0.01) and statin use (P < 0.01) were significantly associated to MPO activity. Fourteen patients who had diabetes and were receiving statin treatment had markedly (P = 0.001) lower median (19.9 versus 41.2 deltaOD630/min per mg protein) MPO activity compared with 18 who had diabetes and were not taking statins. This cross-sectional study suggests that both diabetes and statin treatment affect MPO activity in prevalent HD patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trimethylamine solution, 25 wt. % in H2O
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Supelco
Ethanol-500, 500 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-20 (10 ampules/kit), 20 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-25, 25 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-400 (10 ampules/kit), 400 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Zinc, nanopowder, 40-60 nm avg. part. size, ≥99% trace metals basis
Sigma-Aldrich
Zinc, sputtering target, diam. × thickness 3.00 in. × 0.125 in., 99.995% trace metals basis
Sigma-Aldrich
Zinc, shot, <12 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, sticks, diam. 7-10 mm, 99.97% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 0.25 mm, 99.999% trace metals basis
Sigma-Aldrich
Trimethylamine solution, 25 wt. % in propylene glycol
Sigma-Aldrich
Zinc, pieces, 2-14 mesh, 99.9% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.9%, granular
Supelco
Acetone, analytical standard
Sigma-Aldrich
Cadaverine, purum, ≥97.0% (GC)
Sigma-Aldrich
Trimethylamine solution, 43.0-49.0% in H2O (T)
Sigma-Aldrich
Trimethylamine solution, 31-35 wt. % in ethanol, 4.2 M, contains toluene as stabilizer
Sigma-Aldrich
Reagent Alcohol, anhydrous, ≤0.005% water
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Zinc, shot, 99.9999%
Sigma-Aldrich
Acetone, ≥99.5%, ACS reagent
Sigma-Aldrich
Zinc preparation, 5 g/dL Zn+2 in THF, highly reactive Rieke®metal
Sigma-Aldrich
Zinc, mossy, 99.99% trace metals basis
Sigma-Aldrich
Acetone, ≥99%, meets FCC analytical specifications
Sigma-Aldrich
Zinc, shot, 5 mm, 99.999% trace metals basis
Sigma-Aldrich
Zinc, granular, 20-30 mesh, ACS reagent, ≥99.8%
Sigma-Aldrich
Acetone, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Zinc, dust, <10 μm, ≥98%